Meeting
2014 ASCO Annual Meeting
Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.
Authors
Kenji Tamura
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
Kenji Tamura , Jun Hashimoto , Hitoshi Tsuda , Masayuki Yoshida , Hideko Yamauchi , Kenjiro Aogi , Satoru Shimizu , Hiroji Iwata , Norikazu Masuda , Naohito Yamamoto , Kenichi Inoue , Shinji Ohno , Katsumasa Kuroi , Tamie Sukigara , Yasuhiro Fujiwara , Masashi Andoh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
000003355
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1017)
DOI
10.1200/jco.2014.32.15_suppl.1017
Abstract #
1017
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer.
First Author: Naoko Matsuda
Poster
2013 ASCO Annual Meeting
An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer.
First Author: Tiffany P. Avery
Poster
2016 ASCO Annual Meeting
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.
First Author: Naoko Matsuda
Poster
2013 ASCO Annual Meeting
Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel + cyclophosphamide + capecitabine followed by 5-fluorouracil + epirubicin + cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study).
First Author: Kenji Higaki